Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.
Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.
复制标题
DOI：
10.1016/j.jpain.2021.06.007
复制
发表时间：
2022-01
期刊：
影响因子：
--
通讯作者：
Williams DA
中科院分区：
文献类型：
--
作者：
Boehnke KF;Gagnier JJ;Matallana L;Williams DA
许多患有纤维肌痛的人使用大麻二酚（CBD）产品，尽管有有限的严格证据证明其有益。在目前的研究中，我们对N=878名纤维肌痛患者的横断面调查进行了二次分析，以调查CBD产品选择，使用模式和剂量的自然决策。我们根据过去一年中使用高THC大麻（HTC）的情况对参与者进行了分组（是/否），因为以前的研究表明HTC的使用会影响CBD的使用模式。研究人群主要为女性（93.6%）、白色（91.5%）和平均55.5岁。参与者通常在网上或药房购买CBD产品，购买由个人研究驱动（63%），而不是医疗专业人员的认可（16%）。总体而言，酊剂和外用药是最常见的给药途径。然而，过去一年HTC组的参与者使用吸入途径的频率远远高于那些没有使用吸入途径的人（39.8%对7.1%）。在使用CBD酊剂或食用品的参与者中，每次的平均剂量为每天16毫克和24- 27毫克。然而，大约三分之一的参与者不知道他们使用的CBD剂量。使用吸入和非吸入给药途径的参与者报告的症状缓解程度大于单独使用非吸入途径的参与者。然而，CBD剂量和报告的影响之间没有一致的关系，可能是由于CBD产品的预期效应或个体间的差异。我们的颗粒调查揭示了CBD产品给药方法对纤维肌痛的可变性，以及过去一年HTC的使用如何影响CBD产品的使用。未来的临床试验应该研究低剂量（<50 mg）植物CBD产品的潜在益处。
Many people with fibromyalgia use cannabidiol (CBD) products despite limited rigorous evidence of benefit. In the current study, we conducted a secondary analysis of a cross-sectional survey of N=878 people with fibromyalgia to investigate naturalistic decision making around CBD product choices, use patterns, and dosing. We subgrouped participants based on use of high-THC cannabis (HTC) in the past year (yes/no) as previous studies have shown that HTC use influences CBD use patterns. The study population was largely female (93.6%), white (91.5%) and 55.5 years old on average. Participants typically purchased CBD products online or at dispensaries, with purchasing driven by personal research (63%) rather than endorsement from medical professionals (16%). Overall, tinctures and topicals were the most common administration routes endorsed. However, participants in the past-year HTC group used inhalation routes far more frequently than those who did not (39.8% vs. 7.1%). Among participants using CBD tinctures or edibles, the average dose per session was 16mg and 24-27mg per day. However, approximately one-third of participants did not know what dose of CBD they used. Participants using both inhalation and non-inhalation administration routes reported greater symptom relief than those using non-inhalation routes alone. However, there was no consistent relationship between CBD dose and reported effects, possibly due to expectancy effects around CBD products or interindividual variability. Our granular investigation reveals variability of CBD product dosing practices for fibromyalgia, and how past-year HTC use influences CBD product use. Future clinical trials should investigate the potential benefits of low-dose (<50mg) botanical CBD products.
登录
查看更多内容
影响因子：
4
作者：
Boehnke, Kevin F.;Scott, J. Ryan;Clauw, Daniel J.
通讯作者：
Clauw, Daniel J.
影响因子：
2.9
作者：
CARLINI, EA;CUNHA, JM
通讯作者：
CUNHA, JM
影响因子：
4
作者：
Boehnke, Kevin F.;Scott, J. Ryan;Williams, David A.
通讯作者：
Williams, David A.
影响因子：
4.2
作者：
Capano, Alex;Weaver, Richard;Burkman, Elisa
通讯作者：
Burkman, Elisa
影响因子：
3.8
作者：
Haug NA;Kieschnick D;Sottile JE;Babson KA;Vandrey R;Bonn-Miller MO
通讯作者：
Bonn-Miller MO